organ regeneration using a patient's own lymph nodes
Very little changed between August 21, 2018 and May 13, 2020. LyGenesis kept the same core claim: a patient's lymph nodes can act as in-body bioreactors, donor liver cells can grow there into functioning ectopic liver tissue, and this could help patients with end stage liver disease. The basic commercial pitch also stayed fixed. The company still framed the approach as a way to stretch scarce donor organs much further, with one donor potentially helping dozens of patients. What did change is mostly presentation, not thesis. The 2020 language is a bit tighter about delivery, naming outpatient endoscopic ultrasound rather than the broader outpatient endoscopy phrasing in 2018. That sounds like a more specific procedural description, but it does not amount to a new scientific position. The organ target, disease focus, and replacement-for-transplant ambition all remained stable. Evidence is thin here because both entries read like company positioning, not a before-and-after shift driven by new disclosed data. We can say LyGenesis became slightly more precise in how it described cell delivery. We cannot say, from these two statements alone, that its confidence rose, that the science materially advanced, or that the clinical case changed in a meaningful way. This is mostly continuity.